Clinical trials: Ductal Breast Carcinoma, active
Early Breast Cancer, Ductal Breast Carcinoma In Situ
Hypofractionated Radiotherapy With Concomitant Tumor Bed Boost for Breast Cancer
Hypofractionated breast radiotherapy with concomitant tumor bed boost for early breast cancer or ductal breast carcinoma in situ after partial mastectomy
- Trial name
- HFCBB (NCT06984250)
- Testing
- Hypofractionated Radiation Therapy
- Where
- 2 sites in Taiwan
- Volunteers
- 315 people
- Sponsor
- National Taiwan University Hospital
Urachal Cancer, Advanced Solid Tumor Cancer
Trastuzumab Rezetecan in Advanced Solid Tumors Refractory to Standard Therapies
This study is a single-center, multi-cohort, phase II clinical trial. Eligible patients with HER2-positive advanced solid tumors were enrolled after providing informed consent.
- Conditions
- Urachal Cancer, Advanced Solid Tumor Cancer, Antibody-drug Conjugates
- Trial name
- NCT07309770
- Testing
- SHR-A1811, Trastuzumab Rezetecan
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Sheng Zhang
Ductal Breast Carcinoma In Situ, Invasive Breast Carcinoma
Hypofractionated Radiation Therapy or Standard Radiation Therapy in Treating Patients With Ductal Breast Carcinoma In Situ or Early Invasive Breast Cancer
This randomized phase II trial studies how well hypofractionated radiation therapy (RT) works compared to standard RT in treating patients with ductal breast carcinoma in situ (DCIS) or early invasive breast cancer.
- Conditions
- Ductal Breast Carcinoma In Situ, Invasive Breast Carcinoma, Stage I Breast Cancer AJCC v6, Stage IA Breast Cancer AJCC v7
- Trial name
- NCT01266642
- Testing
- External Beam Radiation Therapy, Hypofractionated Radiation Therapy, Laboratory Biomarker Analysis
- Where
- 7 sites in United States
- Volunteers
- 301 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer
Assessment of Biosignature Classification of DCIS for RadioTherapy Benefit Post Lumpectomy (ABCD RT)
NRG-CC016 is being done to determine if omission of radiation therapy (RT) for patients with biosignature Low Risk (DCISionRT score less than 2.8) DCIS yields no clinically meaningful increase ipsilateral breast recurrence (IBR)…
- Trial name
- ABCD RT (NCT07554573)
- Testing
- Radiation Therapy, Standard of Care Radiation Therapy, No Intervention
- Volunteers
- 5,270 people
- Sponsor
- NRG Oncology
Ductal Carcinoma in Situ of the Breast
Avoiding Surgery in Estrogen Receptor Positive Atypical Ductal Hyperplasia and In-situ Carcinoma Treated With Endocrine Treatment Trial
This study aims to evaluate the 5-year invasive ipsilateral breast cancer incidence rate in patients with hormone-receptor positive, HER-2 negative atypical ductal hyperplasia or in-situ carcimona who omitted surgery and received…
- Trial name
- ASAIN (NCT07245316)
- Testing
- Avoiding surgery
- Where
- South Korea
- Volunteers
- 340 people
- Sponsor
- Jeong Eon Lee
Breast Cancer, Ductal Carcinoma
Randomized Double-Blind Phase II Trial of Baby Exemestane Versus Baby Tamoxifen in Post-Menopausal Women at High Risk for Breast Cancer
The goal of this research study is to evaluate the efficacy and safety of low-dose exemestane versus low-dose tamoxifen in post-menopausal women at high risk for breast cancer.
- Conditions
- Breast Cancer, Ductal Carcinoma, Estrogen-receptor-positive Breast Cancer, Atypical Lobular Hyperplasia
- Trial name
- BabyTEARS (NCT07499999)
- Testing
- Exemestane, Tamoxifen
- Where
- 2 sites in United States
- Volunteers
- 140 people
- Sponsor
- Dana-Farber Cancer Institute
Lobular Breast Carcinoma
Negative/Low Hormone Receptor And/or HER2 POsitive Lobular Invasive Breast Carcinoma - A Real-World International Cohort Study
The NAPOLI Study is a retrospective multicenter observational study designed to characterize hormone receptor-negative/low invasive lobular carcinoma of the breast.
- Trial name
- NAPOLI (NCT07613151)
- Testing
- Upfront Breast Surgery, Adjuvant Radiotherapy, Endocrine Therapy
- Where
- Italy
- Volunteers
- 250 people
- Sponsor
- Istituto Oncologico Veneto IRCCS
Breast Atypical Hyperplasia, Breast Carcinoma
Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer
This phase IIA trial compares the effect of acolbifene versus low dose tamoxifen in preventing breast cancer in premenopausal women at high risk for developing breast cancer.
- Conditions
- Breast Atypical Hyperplasia, Breast Carcinoma, Breast Ductal Carcinoma In Situ, Breast Lobular Carcinoma In Situ
- Trial name
- NCT05941520
- Testing
- Acolbifene Hydrochloride, Biospecimen Collection, Mammography
- Where
- 4 sites in United States
- Volunteers
- 80 people
- Sponsor
- National Cancer Institute (NCI)
Ductal Carcinoma in Situ, Breast Cancer
Novel Cavity Marking Technique in Breast Cancer Patients Undergoing Breast Conservation Surgery With Oncoplastic Reconstruction for the Delivery of Adjuvant Radiotherapy and Accuracy of Recommended Re-excisions
This study will investigate a novel approach to marking surgical cavity margins following tumor resection, to allow for more accurate radiotherapy following oncoplastic surgery.
- Trial name
- NCT06903468
- Testing
- Novel cavity marking technique
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Florida
Breast Cancer
Breast-Conserving Surgery and Whole-Breast Radiation Therapy With or Without Additional Radiation Therapy to the Tumor in Treating Women With Ductal Carcinoma in Situ (BONBIS)
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Giving radiation therapy after surgery may kill any tumor cells that remain after surgery.
- Trial name
- BONBIS (NCT00907868)
- Testing
- partial breast irradiation, whole breast irradiation
- Where
- France
- Volunteers
- 2,004 people
- Sponsor
- Institut du Cancer de Montpellier - Val d'Aurelle
Triple Negative Breast Cancer, HER2-negative Breast Cancer
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
A phase 1a/1b, multicenter, open-label, dose escalation/expansion, multiple-dose study to evaluate the safety and activity of DR-0202 in patients with locally advanced or metastatic, relapsed or refractory carcinomas
- Conditions
- Triple Negative Breast Cancer, HER2-negative Breast Cancer, Non Small Cell Lung Cancer, Cervical Cancer
- Trial name
- NCT06999187
- Testing
- DR-0202
- Where
- 10 sites in United States
- Volunteers
- 96 people
- Sponsor
- Dren Bio
Breast Neoplasms
Single-Fraction Very Accelerated Partial Breast Irradiation (sfVAPBI)
To investigate clinical outcomes, late side effects, and cosmetic results of a single-fraction very accelerated partial breast irradiation as postoperative local treatment for the treatment of early stage breast cancer.
- Trial name
- sfVAPBI (NCT07067437)
- Testing
- single-fraction very accelerated partial breast irradiation
- Where
- 23 sites in France, Germany and 7 more
- Volunteers
- 250 people
- Sponsor
- National Institute of Oncology, Hungary
Ductal Carcinoma in Situ, Lobular Carcinoma in Situ
CAN1012 in Pre-Malignant DCIS and LCIS
This is a Phase I/Ib study evaluating CAN1012 in patients with ductal carcinoma in situ and lobular carcinoma in situ.
- Trial name
- NCT07408856
- Testing
- CAN1012
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Providence Health & Services
Clear Cell Renal Cell Cancer (ccRCC), Pancreatic Ductal Adenocarcinoma (PDAC)
A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors
The main purpose of Part A of the study is to evaluate safety, tolerability and tracer uptake after a single intravenous (IV) administration of [68Ga]Ga-DPI-4452 for each tumor type such as clear cell renal cell cancer (ccRCC)…
- Conditions
- Clear Cell Renal Cell Cancer (ccRCC), Pancreatic Ductal Adenocarcinoma (PDAC), Colorectal Cancer (CRC), Urothelial Carcinoma (UC)
- Trial name
- NCT05706129
- Testing
- [68Ga]Ga-DPI-4452, [177Lu]Lu-DPI-4452
- Where
- 10 sites in Australia, France
- Volunteers
- 270 people
- Sponsor
- Lumara Bio Oncologics GmbH
Breast Carcinoma, Breast Ductal Carcinoma in Situ
A Patient Navigation Program for Addressing Disparities in Breast Cancer Care
This clinical trial evaluates a patient navigation program for addressing disparities in breast cancer care. The navigation program is designed to help improve patient knowledge about clinical and supportive care services…
- Trial name
- NCT06350500
- Testing
- Patient Navigation, Questionnaire
- Where
- United States
- Volunteers
- 126 people
- Sponsor
- Roswell Park Cancer Institute
Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage 1 Breast Cancer AJCC v8
Pre-operative SABR With and Without Caloric Restriction for Early Stage Breast Cancer
This phase II trial studies the effect of calorie reduction while undergoing stereotactic ablative radiation therapy in treating patients with breast cancer.
- Conditions
- Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage 1 Breast Cancer AJCC v8, Anatomic Stage 2 Breast Cancer AJCC v8, Anatomic Stage 3 Breast Cancer AJCC v8
- Trial name
- NCT04959474
- Testing
- Best Practice, Stereotactic Body Radiation Therapy, Resection
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Thomas Jefferson University
Carcinoma, Intraductal, Noninfiltrating
Multimodal Imaging With FAPI-PET/MRI in Breast Carcinoma-In-Situ for Detection of Occult Invasive Cancer
DCIS (ductal carcinoma in situ) is a common pre-stage for breast cancer. The goal of this clinical trial is to learn if FAPI-PET/MRI (an imaging technique with a weakly radioactive drug) helps to diagnose hidden invasive breast…
- Trial name
- MI-CISDIR (NCT06540872)
- Testing
- [68Ga]Ga-FAPI-46
- Where
- 2 sites in Germany
- Volunteers
- 30 people
- Sponsor
- Universität Münster
Ductal Carcinoma in Situ
DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment
The goal of this trial is to see if active surveillance monitoring and hormonal therapy in patients diagnosed with ductal cell carcinoma in situ (DCIS), an early stage of breast cancer, can be an effective management of the…
- Trial name
- NCT06075953
- Testing
- Tamoxifen, Exemestane, Letrozole
- Where
- 30 sites in United States
- Volunteers
- 400 people
- Sponsor
- QuantumLeap Healthcare Collaborative
Lobular Breast Carcinoma
Initial Staging of Lobular Breast Carcinoma: Head to Head Comparison of 68Ga-FAPI-46 and 18F-FDG PET/CT
Lobular Breast cancer staging with 18F-fluorodeoxyglucose positron emission tomography (18F-FDG PET) is not optimal due to the poor accumulation of 18F-FDG in the tumour.
- Trial name
- GALILEE (NCT05931302)
- Testing
- 68Ga-FAPI-46 PET scan
- Where
- Monaco
- Volunteers
- 40 people
- Sponsor
- Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer
DCIS, Breast Cancer
Delayed Sentinel Lymph Node Biopsy in Ductal Cancer in Situ
The trial aims to investigate the use of superparamagnetic iron oxide (SPIO) nanoparticles as a tracer for delayed sentinel lymph node dissection (d-SLND) in patients where upfront axillary surgery (SLND) is oncologically deemed…
- Conditions
- DCIS, Breast Cancer, Breast Neoplasms, Sentinel Lymph Node
- Trial name
- SENTINOT_2 (NCT04722692)
- Testing
- Delayed SLND, Late SLND
- Where
- 9 sites in United States, Hong Kong and 1 more
- Volunteers
- 500 people
- Sponsor
- Uppsala University